Autolus Therapeutics VP Finance resigns; CFO Dolski appointed PAO

Autolus Therapeutics plc

Andrew Mercieca resigned as VP Finance & PAO on Feb 24, 2025, effective August 2025; not due to any disagreement.
CFO Rob Dolski appointed principal accounting officer effective April 3, 2025, in addition to his CFO role.
No additional compensation for Dolski for the added PAO duties; no family or transaction disclosures.
Mercieca's resignation follows a statutory three-month minimum notice period under UK law.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rob Dolski

principal accounting officer

AUTL · Autolus Therapeutics plc

Effective: 2025-04-03
Filed: April 3, 2025, 7:59 PM ET

On April 3, 2025, the Board of Directors of the Company appointed Rob Dolski, the Company’s current Chief Financial Officer, to serve as the principal accounting officer of the Company in addition to his current role as principal financial officer, effective immediately.

Departed

Andrew Mercieca

Vice President of Finance and principal accounting officer

AUTL · Autolus Therapeutics plc

Successor: Rob Dolski
Filed: April 3, 2025, 7:59 PM ET

On February 24, 2025, Andrew Mercieca notified Autolus Therapeutics plc (the “Company”) of his intention to resign from his role as the Company’s Vice President of Finance and principal accounting officer, to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rob Dolski was appointed as principal accounting officer at Autolus Therapeutics plc.

Action: appointed
Role: principal accounting officer

Exact text from the filing

On April 3, 2025, the Board of Directors of the Company appointed Rob Dolski, the Company’s current Chief Financial Officer, to serve as the principal accounting officer of the Company in addition to his current role as principal financial officer, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Mercieca resigned as Vice President of Finance and principal accounting officer at Autolus Therapeutics plc.

Action: resigned
Role: Vice President of Finance and principal accounting officer

Exact text from the filing

On February 24, 2025, Andrew Mercieca notified Autolus Therapeutics plc (the “Company”) of his intention to resign from his role as the Company’s Vice President of Finance and principal accounting officer, to pursue another opportunity.

View on SEC.gov

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001193125-25-072356

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.